Highlight
– AZD0120 (GC012F), a BCMA/CD19 dual-target autologous CAR‑T produced on Gracell’s FasTCAR platform, reported an objective response rate (ORR) of 100% (15/15 evaluable) in an early Phase Ib US study (DURGA‑1) presented at ASH 2025.
– Deep responses were rapid (median time to response 0.9 months), with 5 complete remissions and all 8 patients tested for MRD by next‑generation sequencing (NGS) found MRD‑negative.
– Safety signals were notable for a 64% incidence of cytokine release syndrome (CRS) with no grade ≥3 CRS and no reported ICANS or other neurotoxicity in this dataset.
Background and Unmet Need
Relapsed or refractory multiple myeloma (RRMM) remains a disease with substantial unmet need despite advances in immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, and cellular therapies. B‑cell maturation antigen (BCMA) has emerged as a validated target for myeloma, with autologous BCMA-directed CAR‑T cell therapies achieving high response rates and regulatory approvals. Nonetheless, challenges persist: antigen escape, durability of response, manufacturing lead time, and treatment‑related toxicities such as cytokine release syndrome (CRS) and immune effector cell‑associated neurotoxicity syndrome (ICANS).
Dual-target CAR designs (e.g., BCMA plus CD19) aim to reduce antigen escape and potentially broaden efficacy by engaging multiple tumor-associated antigens. Rapid manufacturing platforms that preserve favorable T‑cell phenotypes (naïve and central memory) could shorten vein‑to‑vein time and improve product potency.
Study Design: DURGA‑1 (NCT05850234)
DURGA‑1 is an open‑label, single‑arm, multicenter Phase Ib study conducted in the United States evaluating AZD0120 (GC012F), an autologous BCMA/CD19 dual‑target CAR‑T product acquired by AstraZeneca through its 2023 purchase of Gracell (now under AstraZeneca control).
Key elements:
- Population: Patients with relapsed or refractory multiple myeloma who had received at least three prior lines of therapy.
- Dosing cohorts: Two dose levels were evaluated — 1×10^5 and 3×10^5 CAR‑T cells/kg.
- Primary objectives: Safety and tolerability.
- Secondary/exploratory objectives: Preliminary efficacy assessments including objective response rate (ORR), complete remission (CR) rates, minimal residual disease (MRD) status by NGS, time to response, and durability of response.
- Enrollment reported: 25 patients treated in the trial; 15 patients were evaluable for efficacy in the dataset disclosed at ASH 2025.
Key Findings and Interpretation
Efficacy
Among 15 evaluable patients, AZD0120 achieved an ORR of 100% (15/15), with 5 patients meeting criteria for complete remission (CR). The median time to response was rapid at 0.9 months. MRD assessment by NGS was performed in 8 patients; all 8 were MRD‑negative at the sensitivity reported. These early results suggest potent anti‑myeloma activity with deep and rapid responses in heavily pretreated patients.
Clinical interpretation:
- The 100% ORR in a small evaluable cohort is striking and supports the biological rationale for dual‑targeting BCMA and CD19 as a strategy to achieve deep remissions.
- Rapid kinetics of response (median 0.9 months) are consistent with robust in vivo expansion and activity of the infused CAR‑T cells, which the FasTCAR manufacturing process is reported to favor by preserving less differentiated T‑cell subsets.
- NGS‑confirmed MRD negativity in all tested patients is encouraging, but the small sample and lack of standardized follow‑up time limit conclusions about durability.
Safety
Safety signals in the disclosed cohort were notable for the following:
- CRS occurred in approximately 64% of patients, but no grade 3 or higher CRS events were reported in the dataset presented.
- No cases of ICANS (immune effector cell‑associated neurotoxicity syndrome) or other non‑ICANS neurotoxicity were reported.
- Other adverse event details, hematologic toxicities, infections, or long‑term safety data were not fully disclosed in the early presentation.
Clinical interpretation:
- Lower rates of high‑grade CRS and an absence of reported neurotoxicity—if confirmed with larger numbers and longer follow‑up—would differentiate AZD0120 favorably from earlier CAR‑T products, which have carried non‑trivial rates of grade ≥3 CRS and ICANS.
- However, early phase, small‑cohort safety signals can be misleading; rare but serious toxicities often emerge with broader exposure and longer observation.
Manufacturing and Platform Features
AZD0120 is manufactured using Gracell’s FasTCAR rapid‑manufacture platform, which the developers report can produce CAR‑T products within days rather than the several weeks typically required for conventional manufacturing. The platform is also said to preserve naïve and central memory T‑cell phenotypes, which are associated in preclinical and clinical studies with better proliferation, persistence, and antitumor efficacy.
Clinical and operational implications:
- Shorter manufacturing time could reduce bridging therapy needs, lower dropout during vein‑to‑vein intervals, and improve logistical feasibility for patients with aggressive disease.
- If the FasTCAR process reliably preserves favorable T‑cell subsets, this may contribute to the observed rapid expansion and depth of response. Demonstrating consistent product composition and function across larger, multicenter cohorts will be critical.
Context with Existing BCMA CAR‑T Therapies
Several autologous BCMA‑targeted CAR‑T therapies have achieved regulatory approvals and clinical adoption. These agents demonstrated high response rates in heavily pretreated RRMM, but durability and safety profiles have varied, and antigen escape remains a cause of relapse in some patients. Dual‑target strategies aim to address antigen escape; AZD0120’s early deep responses and MRD negativity are biologically plausible benefits of this approach.
Comparative caveat: cross‑trial comparisons are inherently limited by differences in patient populations, prior therapies, eligibility criteria, manufacturing platforms, and follow‑up duration. Definitive positioning of AZD0120 will require randomized data or large, well‑controlled comparative studies and longer follow‑up.
Expert Commentary and Limitations
Strengths of the report:
- Dual‑targeting strategy with rapid responses and high depth of remission.
- Potentially favorable acute safety profile in this small cohort.
- Rapid manufacturing could materially improve patient access and reduce time‑sensitive dropouts.
Key limitations to bear in mind:
- Small sample size and limited number of evaluable patients (15 evaluable of 25 treated) restrict external validity and increase the risk of selection bias.
- Short median follow‑up was not reported in detail in the early ASH disclosure; durability outcomes such as progression‑free survival (PFS) and overall survival (OS) remain immature.
- Unreported granular safety data (e.g., cytopenias duration, infection rates, on‑target off‑tumor effects) are necessary to fully evaluate tolerability.
- Absence of a comparator arm prevents definitive conclusions about whether dual targeting or the FasTCAR platform is causative of the observed outcomes versus patient selection or other factors.
Additional points experts will watch:
- Durability of MRD negativity and its correlation with PFS/OS.
- Reproducibility of safety profile in larger cohorts and real‑world settings.
- Manufacturing scalability, batch consistency, and logistics across international sites.
Conclusion and Next Steps
The DURGA‑1 Ib data for AZD0120 (GC012F) presented at ASH 2025 provide an encouraging signal of potent, rapid, and deep anti‑myeloma activity in heavily pretreated RRMM with an apparently favorable acute safety profile. The dual BCMA/CD19 targeting strategy combined with a rapid FasTCAR manufacturing platform offers a plausible mechanistic and operational advantage.
However, these preliminary results must be interpreted cautiously. Confirmation requires larger, preferably randomized studies, standardized and longer MRD and clinical follow‑up to assess durability, and comprehensive safety reporting. If subsequent cohorts and later‑phase trials validate these early findings, AZD0120 could become an important addition to the RRMM treatment armamentarium and may influence manufacturing expectations for future autologous CAR‑T products.
Funding and ClinicalTrials.gov
AZD0120 (GC012F) development became part of AstraZeneca’s cell therapy portfolio following its acquisition of a controlling interest in Gracell in December 2023 (reported purchase price: US$1.2 billion). AstraZeneca also expanded its cellular therapy capabilities with additional deals and acquisitions focused on in vivo and solid‑tumor CAR‑T approaches.
Key trial identifier: DURGA‑1 — ClinicalTrials.gov NCT05850234.
References
1) Pharmaphorum coverage of AstraZeneca/Gracell data presented at ASH 2025: https://pharmaphorum.com/ (article summarizing AZD0120/DURGA‑1 disclosures).
2) ClinicalTrials.gov identifier for DURGA‑1: NCT05850234. https://clinicaltrials.gov/ct2/show/NCT05850234
3) U.S. Food and Drug Administration: Abecma (idecabtagene vicleucel) approval information. https://www.fda.gov/news-events/press-announcements/fda-approves-new-cell-based-therapy-treatment-multiple-myeloma
4) U.S. Food and Drug Administration: Carvykti (ciltacabtagene autoleucel) approval information. https://www.fda.gov/news-events/press-announcements/fda-approves-carvykti-another-cell-based-therapy-multiple-myeloma
Note: Readers seeking in‑depth peer‑reviewed comparisons of approved BCMA CAR‑T products and CAR‑T toxicities may consult the primary regulatory reviews and comprehensive contemporary reviews in hematology/oncology journals.